Table 4 Response among patients with AML-MRC preselected to receive LDAC and treated with azacitidine or LDAC
Patients with AML-MRC preselected to receive LDAC (n = 160) | ||||
|---|---|---|---|---|
AZA (n = 81) | LDAC (n = 79) | |||
n (%) | ||||
Overall Response Rate (CR + CRi) | 22 (27.2) | 11 (13.9) | ||
CR | 17 (21.0) | 10 (12.7) | ||
CRi | 5 (6.2) | 1 (1.3) | ||
Partial remission | 1 (1.2) | 1 (1.3) | ||
Stable disease | 30 (37.0) | 30 (38.0) | ||
Progressive disease | 4 (4.9) | 11 (13.9) | ||
LDAC-preselected Intermediate-risk cytogenetics | LDAC-preselected Poor-risk cytogenetics | |||
AZA (n = 47) | LDAC (n = 33) | AZA (n = 34) | LDAC (n = 46) | |
n (%) | ||||
Overall Response Rate (CR + CRi) | 15 (31.9) | 6 (18.2) | 7 (20.6) | 5 (10.9) |
CR | 12 (25.5) | 6 (18.2) | 5 (14.7) | 4 (8.7) |
CRi | 3 (6.4) | 0 | 2 (5.9) | 1 (2.2) |
Partial remission | 1 (2.1) | 1 (3) | 0 | 0 |
Stable disease | 19 (40.4) | 15 (45.5) | 11 (32.4) | 15 (32.6) |
Progressive disease | 4 (8.5) | 2 (6.1) | 0 | 9 (19.6) |
LDAC-preselected age 65–74 years | LDAC-preselected age ≥ 75 years | |||
AZA (n = 26) | LDAC (n = 38) | AZA (n = 55) | LDAC (n = 41) | |
n (%) | ||||
Overall Response Rate (CR + CRi) | 10 (38.5) | 7 (18.4) | 12 (21.8) | 4 (9.8) |
CR | 7 (26.9) | 6 (15.8) | 10 (18.2) | 4 (9.8) |
CRi | 3 (11.5) | 1 (2.6) | 2 (3.6) | 0 |
Partial remission | 0 | 1 (2.6) | 1 (1.8) | 0 |
Stable disease | 9 (34.6) | 18 (47.4) | 21 (38.2) | 12 (29.3) |
Progressive disease | 2 (7.7) | 4 (10.5) | 2 (3.6) | 7 (17.1) |